All In Biotech

NDA 018989 · Haleon US Holdings

Advil

Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug

Priority review

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

May 18, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

242,513

162,780 serious, 17,616 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 3, 2026.

Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 18, 1984 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • ADVIL · IBUPROFEN 200MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective22,463
  • pain17,526
  • fatigue17,259
  • nausea16,289
  • headache14,689
  • arthralgia12,623
  • dyspnoea12,006
  • diarrhoea11,537
  • vomiting11,441
  • rash10,335
  • off label use10,109
  • dizziness9,950

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,060
20052,687
20062,775
20072,428
20082,290
20093,325
20104,785
20116,164
20128,429
20139,577
20149,290
201513,284
201617,083
201714,686
201818,092
201918,861
202017,480
202118,758
202216,498
202315,344
202414,286
202514,363
20269,958

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,679 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.